相关实验视频

Updated: Jun 13, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

系统性硬化症患者的巨细胞动脉炎:一个病例系列

Max Guarda¹, Alexandria Roy², Michelle Burke³

¹Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. maxguarda@gmail.com.

Clinical and experimental rheumatology

|March 25, 2024

概括

系统性硬化症 (SSc) 患者的巨细胞动脉炎 (GCA) 是罕见的. 葡萄糖皮质类药物对GCA并没有引起硬皮质危机 (SRC),即使在患者有SRC病史之前. 托西利兹马布的使用方法

科学领域:

类风湿病学类风湿病学
内部医学内部医学
血管炎是一种血管炎.

背景情况:

巨细胞动脉炎 (GCA) 和全身性硬化症 (SSc) 是不同的自身免疫性疾病.
GCA和SSc的同时发生非常罕见,对最佳管理的理解有限.
由于潜在的重叠症状和并发症,在SSc患者中确定GCA的治疗策略至关重要.

研究的目的:

描述最大的单一机构病例系列,包括被诊断患有GCA和SSc的患者.
分析这种罕见患者队列中的临床表现,诊断方法,治疗方法和结果.
调查GCA在SSc患者的葡萄糖皮质类药物治疗的安全性,特别是关于硬化硬质的危机 (SRC).

主要方法:

从1996年到2020年,对具有SSc和GCA诊断代码的患者进行了回顾性审查.
纳入标准要求由风湿病学家对SSc和GCA进行正式诊断.
抽象的数据包括人口统计,临床特征,诊断方式,治疗方法和患者的结果.

主要成果:

确定了8名女性患者,其中大多数符合GCA和SSc的分类标准.
三名有SRC病史的患者在开始服用GCA.glucocorticoid后没有出现新的SRC发作.
托西利祖马布在3名患者中使用;其中1名患者出现严重并发症,另1名患者由于无关问题而停止治疗,另1名患者实现了缓解.

结论:

这一病例系列代表了同时患有GCA和SSc.的最大报告的患者队列.
对GCA的葡萄糖皮质类药物治疗在SSc患者的SRC沉方面似乎是安全的,即使是那些有SRC病史的人.
需要进一步的研究来评估托西利祖马布在SSc.的背景下管理GCA的疗效和安全性.

更多相关视频

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...